Teleflex Incorporated
TFX Healthcare Medical Instruments & Supplies
Teleflex Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 17.2% from fiscal 2024.
- Revenue
- +28.9%
- EPS
- −17.3%
- Free cash flow
- +220.1%
- Total debt
- +47.7%
Quarter to June 2026, against a year earlier
Follow TFX
Alert me
Teleflex Incorporated (TFX) P/S ratio
As of 5 November 2026, Teleflex Incorporated (TFX) trades at a P/S ratio of 2.9×. Over the past ten years it has ranged from 2.2× (January 2026) to 8.2× (April 2021); the current reading is higher than 13% of that period. That is above the Medical Instruments & Supplies industry median of 2.5× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 2.7× | (44.28%) |
| FY2024 | 4.9× | 24.00% |
| FY2023 | 4.0× | (5.78%) |
| FY2022 | 4.2× | (23.23%) |
| FY2021 | 5.5× | (27.48%) |
| FY2020 | 7.5× | 12.54% |
| FY2019 | 6.7× | 38.92% |
| FY2018 | 4.8× | (9.69%) |
| FY2017 | 5.3× | 44.97% |
| FY2016 | 3.7× | 22.06% |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 2.4× | (1.60%) |
| Mar 2026 | 2.5× | (8.92%) |
| Dec 2025 | 2.7× | (5.80%) |
| Sep 2025 | 2.9× | (4.49%) |
| 42 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| BLCO Bausch + Lomb Corporation compare | 1.3× |
| NVST Envista Holdings Corporation compare | 1.4× |
| AVTR Avantor, Inc. compare | 1.5× |
| MMED MiniMed Group, Inc. compare | 1.7× |
| ICUI ICU Medical, Inc. compare | 1.9× |
| ATR AptarGroup, Inc. compare | 2.3× |
| TFX Teleflex Incorporated | 2.9× |
| MMSI Merit Medical Systems, Inc. compare | 3.3× |
| PLSE Pulse Biosciences, Inc compare | 2,559× |
| Medical Instruments & Supplies industry median | 2.5× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on TFX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement